

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A pharmaceutical composition comprising (a) a compound selected from aripiprazole or a metabolite of aripiprazole wherein the metabolite of aripiprazole is selected from the group consisting of dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD in combination with (b) at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof, at least one carbostyryl derivative in combination with at least one serotonin reuptake inhibitor.

2-36. (canceled).

37. (new): A pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, setraline and salts thereof.

38. (new): The pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and a salt thereof.

39. (new): The composition of claim 37 wherein the at least one serotonin reuptake inhibitor is citalopram.

40. (new): The composition of any one of claims 1, 37, 38 and 39, wherein aripiprazole is anhydrous aripiprazole crystals B.

41. (new): The composition of any one of claims 1, 37, 38 and 39, further comprising at least one pharmaceutically acceptable carrier.

42. (new): The composition of any one of claims 1, 37, 38 and 39 being useful for treatment of mood disorders.

43. (new): The composition of claim 42 wherein the mood disorder is depression or major depressive disorder.

44. (new): The composition of claim 42 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

45. (new): The composition of any one of claims 1, 37, 38 and 39 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease

with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

46. (new): A pharmaceutical composition comprising at least one metabolite of aripiprazole selected from the group consisting of dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

47. (new): The composition of claim 46 wherein the at least one serotonin reuptake inhibitor is citalopram.

48. (new): The composition of claim 46 wherein the at least one serotonin reuptake inhibitor is escitalopram.

49. (new): The composition of any one of claims 46 to 48, further comprising at least one pharmaceutically acceptable carrier.

50. (new): The composition of any one of claims 46 to 48 being useful for treatment of mood disorders.

51. (new): The composition of claim 50 wherein the mood disorder is depression or major depressive disorder.

52. (new): The composition of claim 50 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

53. (new): The composition of any one of claims 46 to 48 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

54. (new): A method of treating mood disorders in a patient comprising administration of an effective amount of a pharmaceutical composition which comprise(s) a compound selected from aripiprazole or metabolite of aripiprazole wherein the metabolite of aripiprazole is selected from the group consisting of dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD in combination with (b) at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

55. (new): A method of treating mood disorders in a patient comprising administration of an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine,

duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline and salts thereof.

56. (new): The method of treating mood disorders in a patient comprising administration of an effective amount of a pharmaceutical composition comprising aripiprazole in combination with at least one serotonin reuptake inhibitor selected from escitalopram and salt thereof.

57. (new): The method of claim 55 wherein at least one serotonin reuptake inhibitor is citalopram.

58. (new): The method of any one of claims 54 to 57 wherein aripiprazole is anhydrous aripiprazole crystals B.

59. (new): The method of any one claims 54 to 57, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.

60. (new): The method of any one claims 54 to 57, wherein the mood disorder is depression of major depressive disorder.

61. (new): The method of any one of claims 54 to 57, wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

62. (new): The method of any one of claims 54 to 57, wherein the mood disorders are major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

63. (new): A method of treating a mood disorder in a patient comprising administration of an effective amount of pharmaceutical composition comprising at least one metabolite of aripiprazole selected from the group consisting of dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD in combination with at least one serotonin reuptake inhibitor selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

64. (new): A method of claim 63 wherein the at least one serotonin reuptake inhibitor is citalopram.

65. (new): The method of claim 63 wherein the at least one serotonin reuptake inhibitor is escitalopram.

66. (new): The method of any one of claims 63 to 65 wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.

67. (new): The method of any one of claims 63 to 65 wherein the mood disorder is depression of major depressive disorder.

68. (new): The method of any one of claims 63 to 65 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

69. (new): The method of any one of claims 63 to 65 wherein the mood disorders are major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.